Skip to main content

HighCape Capital Acquisition Corp. II (HCCR)

HighCape Capital Acquisition II will go public soon, but the exact IPO date is still unknown.
Stock Price: $10.00
Confirmed IPO price

Company Description

HighCape Capital Acquisition II is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

We intend to focus on industries that complement our management team’s background in life sciences and life sciences related industries, and to capitalize on the ability of our management team to identify and acquire a business within those industries.

We intend to focus our investment effort broadly across the entire life sciences industry, which encompasses therapeutics, devices, diagnostics, medical information technology and digital health companies.

We were formed by our sponsor, which is an affiliate of HighCape, a life sciences investment firm with a focus on active investing in commercial stage companies.

HighCape typically invests in companies that have FDA cleared products and are at the point of product launch or have already generated revenue for multiple years.

Collectively, this group has been actively involved in initial public offerings and exits totaling in excess of $5 billion.

HighCape Capital Acquisition Corp. II
CountryUnited States
Founded2021
IPO DatePending
IndustryBlank Checks / SPAC
CEOKevin Rakin

Contact Details

Address:
452 Fifth Avenue, 21st Floor
New York, NY 10018
United States
Phone(646) 793-3510

Stock Details

Ticker SymbolHCCR
ExchangeNASDAQ
Reporting CurrencyUS Dollars
IPO Price$10.00
CIK Code1846064
Employer ID86-1977840

Key Executives

NamePosition
Kevin RakinChief Executive Officer and Chairman of the Board of Directors
Matt ZugaChief Financial Officer, Chief Operating Officer and Director
David ColpmanDirector Nominee
Antony Loebel, M.D.Director Nominee
Robert TaubDirector Nominee